References
- Doster B, Murray FJ, Newman R, Woolpert SF. Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials. Am Rev Respir Dis 1973;107:177–190.
- Walker CB. Visual screener for ethambutol toxicity. Lancet 1968;2:493–494.
- Citron KM. Ethambutol: a review with special reference to ocular toxicity. Tubercle 1969;50(Suppl):32–36.
- Barron GJ, Tepper L, Iovine G. Ocular toxicity from ethambutol. Am J Ophthalmol 1974;77:256–260.
- Behbehani RS, Affel EL, Sergott RC, Savino PJ. Multifocal ERG in ethambutol associated visual loss. Br J Ophthalmol 2005;89:976–982.
- Heng JE, Vorwerk CK, Lessell E, Zurakowski D, Levin LA, Dreyer EB. Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway. Invest Ophthalmol Vis Sci 1999;40:190–196.
- Choi SY, Hwang JM. Optic neuropathy associated with ethambutol in Koreans. Korean J Ophthalmol 1997;11:106–110.
- Goyal JL, De S, Singh NP, Bhatia A. Evaluation of visual functions in patients on ethambutol therapy for tuberculosis: a prospective study. J Commun Dis 2003;35:230–243.
- Kumar A, Sandramouli S, Verma L, Tewari HK, Khosla PK. Ocular ethambutol toxicity: is it reversible? J Clin Neuroophthalmol 1993;13:15–17.
- Sivakumaran P, Harrison AC, Marschner J, Martin P. Ocular toxicity from ethambutol: a review of four cases and recommended precautions. N Z Med J 1998;111:428–430.
- Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, Olivier KN. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970–976.
- Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ Jr. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2005;172:250–253.
- Pierce M, Crampton S, Henry D, Heifets L, LaMarca A, Montecalvo M, Wormser GP, Jablonowski H, Jemsek J, Cynamon M, Yangco BG, Notario G, Craft JC. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384–391.
- Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. Am Rev Respir Dis 1992;146:285–289.
- Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson RE, Eron LJ, Sparti PD, Bihari B, Kaufman DL. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828–833.
- Sadun AA, Wang MY. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year. J Neuroophthalmol 2008;28:265–268.
- Zoumalan CI, Agarwal M, Sadun AA. Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2005;243:410–416.
- Sinha MK, Garg RK, Anuradha H, Agarwal A, Singh MK, Verma R, Shukla R. Vision impairment in tuberculous meningitis: predictors and prognosis. J Neurol Sci 2010;290:27–32.
- Duque-Silva A, Robsky K, Flood J, Barry PM. Risk factors for central nervous system tuberculosis. Pediatrics 2015;136:e1276–e1284.
- Ellis ME, Halim MA, Coates RK, al-Hokail AA, Hussain Qadri SM, el-Yazigi A. Diagnostic dilemma and therapeutic non-compliance in a case of intracranial tuberculoma. Tubercle 1991;72:299–303.